Variant Pharmaceuticals Secures $10 Million in Financing from Korean Company, Incon Co., Ltd.

Funds will accelerate clinical development of VAR 200, 2-hydroxypropyl-beta-cyclodexrtrin (2HPβCD), for treatment of focal segmental glomerulosclerosis (FSGS), a rare kidney disease Incon's investment in Variant expands their biopharmaceutical busi... Biopharmaceuticals, Venture Capital, Personnel Variant Pharmaceuticals, Glomerulosclerosis, Alport Syndrome
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news